Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Assessment of the pathogenicity of Y. enterocolitica B1A isolates from San Luis, Argentina.
Gene
January 2025
Área Microbiología e Inmunología, Facultad de Química, BioquímicaArgentina y Farmacia, Universidad Nacional de San Luis, Ejercito de los Andes 950, P. O. 5700 San Luis, Argentina. Electronic address:
Yersinia enterocolitica, a bacterial enteropathogen that produces a variety of clinical manifestations in humans, includes six biotypes (B), called 1A, 1B, 2, 3, 4 and 5 and about 70 serotypes. The biotypes exhibit diverse pathogenic potential; while 1B and 2-5 may show ability to produce clinical symptoms due to the presence of chromosomal and plasmid (pYV) virulence genes, B1A is supposed a non-pathogenic biotype since it lacks pYV plasmid. Therefore, although B1A strains cause diarrhea in humans, their pathogenic potential has not yet been extensively studied.
View Article and Find Full Text PDFPhase 1 Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3 in Patients with Advanced Solid Tumors.
Clin Cancer Res
January 2025
University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Purpose: Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is essential for the survival and immune sequestration of cancer cells. We conducted a phase 1 study of TTI‑101, a first-in-class, selective small-molecule inhibitor of STAT3, in patients with advanced metastatic cancer.
Patients And Methods: Patients were treated with TTI-101 orally twice daily in 28-day cycles at 4 dose levels (DLs): 3.
2'-Fucosyllactose inhibits human norovirus replication in human intestinal enteroids.
J Virol
January 2025
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Unlabelled: Human noroviruses (HuNoVs) are the leading cause of acute gastroenteritis worldwide. Currently, there are no targeted antivirals for the treatment of HuNoV infection. Histo-blood group antigens (HBGAs) on the intestinal epithelium are cellular attachment factors for HuNoVs; molecules that block the binding of HuNoVs to HBGAs thus have the potential to be developed as antivirals.
View Article and Find Full Text PDFReal-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain.
Ther Adv Med Oncol
January 2025
Centro Integral Oncológico Clara Campal HM CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain.
Treatment with pegylated nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (folinic acid; 5-FU/LV) has demonstrated remarkable efficacy for metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical trials. However, real-world data on the effectiveness of nal-IRI+5-FU/LV is heterogeneous and is lacking in Spain. To assess the effectiveness and safety of nal-IRI+5-FU/LV in real-life PDAC patients in Spain.
View Article and Find Full Text PDFBrentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
J Clin Oncol
January 2025
St Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea.
Purpose: In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated the efficacy and safety of BV + Len + R versus placebo + Len + R in patients with R/R DLBCL.
Methods: ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing BV + Len + R with placebo + Len + R in patients with R/R DLBCL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!